Skip to main content
×
Home
    • Aa
    • Aa

Nutrition and the HIV-associated lipodystrophy syndrome

  • Cathríona Rosemary Loonam (a1) and Anne Mullen (a1)
Abstract

HIV-associated lipodystrophy syndrome (HALS), comprising metabolic and morphological alterations, is a known side effect of highly active antiretroviral therapy (HAART). Evidence for the role of nutrition in the management of the systemic parameters of HALS is currently limited. In the present paper we review the current knowledge base surrounding HALS, focusing particularly on the role of nutrition in mitigating the systemic parameters of the syndrome. Reported prevalence of HALS was found to vary from 9 to 83 % due to lack of a standardised definition, as well as variations in assessment methods and in the study population used. HALS is associated with both morphological (lipoatrophy, lipohypertrophy) and metabolic (dyslipidaemia, glucose intolerance, diabetes, hypertension, endothelial dysfunction and atherosclerosis) alterations, which may occur singly or in combination, and are associated with an increased risk of CVD. HAART-induced adipocyte inflammation, oxidative stress and macrophage infiltration, as well as altered adipocyte function and mitochondrial toxicity, have been shown to be central to the development of HALS. The adipocyte, therefore, represents a plausible target for treatment. Pharmacological and surgical treatment interventions have shown effect. However, their use is associated with numerous adverse effects and complications. Targeted lifestyle interventions may provide a useful alternative for managing HALS owing to their safety and tolerability. A Mediterranean-style diet has been found to be effective in improving the systemic parameters of HALS. Furthermore, the effects of n-3 PUFA supplementation are encouraging and future randomised controlled trials investigating the beneficial effects of n-3 PUFA in HALS are justified.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Nutrition and the HIV-associated lipodystrophy syndrome
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Nutrition and the HIV-associated lipodystrophy syndrome
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Nutrition and the HIV-associated lipodystrophy syndrome
      Available formats
      ×
Copyright
Corresponding author
*Corresponding author: Dr Anne Mullen, fax +44 20 7848 4171, email anne.mullen@kcl.ac.uk
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1 S Reynolds & T Quinn (2010) Setting the stage: current state of affairs and major challenges. Clin Infect Dis 50, Suppl. 3, S71S76.

5 MP de Béthune (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res 85, 7590.

8 E De Clercq (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 38, 153179.

9 TN Kakuda (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22, 685708.

11 GH Wynn , MJ Zapor , BH Smith , et al. (2004) Antiretrovirals, part 1: overview, history, and focus on protease inhibitors. Psychosomatics 45, 262270.

12 ML Greenberg & N Cammack (2004) Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54, 333340.

15 MP Dubé , DL Johnson , JS Currier , et al. (1997) Protease inhibitor-associated hyperglycaemia. Lancet 350, 713714.

17 RL Hengel , NB Watts & JL Lennox (1997) Benign symmetric lipomatosis associated with protease inhibitors. Lancet 350, 1596.

19 R Viraben & C Aquilina (1998) Indinavir-associated lipodystrophy. AIDS 12, F37F39.

24 SW Worm , N Friis-Møller , M Bruyand , et al. (2010) High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 24, 427435.

25 K Samaras , H Wand , M Law , et al. (2007) Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria. Diabetes Care 30, 113119.

28 TT Brown , SR Cole , X Li , et al. (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 165, 11791184.

32 K Mondy , E Overton , J Grubb , et al. (2007) Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 44, 726734.

34 S Matetzky , M Domingo , S Kar , et al. (2003) Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 163, 457460.

37 N Friis-Møller , R Thiébaut , P Reiss , et al. (2010) Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 17, 491501.

38 G Guaraldi , S Zona , N Alexopoulos , et al. (2009) Coronary aging in HIV-infected patients. Clin Infect Dis 49, 17561762.

44 S Tsiodras , K-A Poulia , M Yannakoulia , et al. (2009) Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. Metabolism 58, 854859.

46 DL Jacobson , AM Tang , D Spiegelman , et al. (2006) Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 43, 458466.

47 ME Sobieszczyk , DR Hoover , K Anastos , et al. (2008) Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 48, 272280.

48 PC Tien , SR Cole , CM Williams , et al. (2003) Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 34, 461466.

49 A Norris & HM Dreher (2004) Lipodystrophy syndrome: the morphologic and metabolic effects of antiretroviral therapy in HIV infection. J Assoc Nurses AIDS Care 15, 4664.

50 P Benn , C Ruff , J Cartledge , et al. (2003) Overcoming subjectivity in assessing facial lipoatrophy: is there a role for three-dimensional laser scans? HIV Med 4, 325331.

52 FDA Boufassa , AS Lascaux , L Meyer , et al. (2001) Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials 2, 339345.

54 M Galli , A Cozzi-Lepri , AL Ridolfo , et al. (2002) Incidence of adipose tissue alterations in first-line antiretroviral therapy: The LipoICoNa Study. Arch Intern Med 162, 26212628.

55 M Galli , F Veglia , G Angarano , et al. (2003) Gender differences in antiretroviral drug-related adipose tissue alterations: women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 34, 5861.

59 EM Mutimura , AP Stewart , PMD Rheeder , et al. (2007) Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 46, 451455.

60 A Nguyen , A Calmy , V Schiffer , et al. (2008) Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006. HIV Med 9, 142150.

63 T Saint-Marc , M Partisani , I Poizot-Martin , et al. (2000) Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 14, 3749.

64 R Thiébaut , V Daucourt , P Mercié , et al. (2000) Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 31, 14821487.

65 KA Lichtenstein , DJ Ward , AC Moorman , et al. (2001) Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15, 13891398.

66 KV Heath , J Singer , MV O'Shaughnessy , et al. (2002) Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr 31, 211217.

69 KA Lichtenstein , KM Delaney , C Armon , et al. (2003) Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 32, 4856.

71 J van Griensven , L De Naeyer , T Mushi , et al. (2007) High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 101, 793798.

72 S Walmsley , A Cheung , G Fantus , et al. (2008) A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy. HIV Clin Trials 9, 314323.

73 D Jevtovic , G Dragovic , D Salemovic , et al. (2009) The metabolic syndrome, an epidemic among HIV-infected patients on HAART. Biomed Pharmacother 63, 337342.

74 S Mercier , NFN Gueye , A Cournil , et al. (2009) Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case–control study. J Acquir Immune Defic Syndr 51, 224230.

76 C Gervasoni , AL Ridolfo , G Trifiro , et al. (1999) Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 13, 465471.

78 KV Heath , RS Hogg , KJ Chan , et al. (2001) Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 15, 231239.

81 M Savès , F Raffi , J Capeau , et al. (2002) Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 34, 13961405.

82 A Carr , S Emery , M Law , et al. (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case–control study. Lancet 361, 726735.

84 J Fellay , B Ledergerber , E Bernasconi , et al. (2001) Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358, 13221327.

87 C Jericó , H Knobel , M Montero , et al. (2005) Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 28, 132137.

88 A Elgalib , M Aboud , R Kulasegaram , et al. (2011) The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. Curr Med Res Opin 27, 6369.

90 E Gkrania-Klotsas & A-E Klotsas (2007) HIV and HIV treatment: effects on fats, glucose and lipids. Br Med Bull 84, 4968.

93 SH Han , J Zhou , S Saghayam , et al. (2011) Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocr J 58, 475484.

94 C Wanke , B Polsky & D Kotler (2002) Guidelines for using body composition measurement in patients with human immunodeficiency virus infection. AIDS Patient Care STDS 16, 375388.

95 A Carr , M Law & HIV Lipodystrophy Case Definition Study Group (2003) An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 33, 571576.

96 J Fontdevila , JM Serra-Renom , M Raigosa , et al. (2008) Assessing the long-term viability of facial fat grafts: an objective measure using computed tomography. Aesthet Surg J 28, 380386.

98 A Carr , K Samaras , A Thorisdottir , et al. (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353, 20932099.

99 S Safrin & C Grunfeld (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS 13, 24932505.

105 S Grinspoon & A Carr (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352, 4862.

106 DL Jacobson , T Knox , D Spiegelman , et al. (2005) Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 40, 18371845.

107 KD Miller , E Jones , JA Yanovski , et al. (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351, 871875.

108 WL Dinges , D Chen , PG Snell , et al. (2005) Regional body fat distribution in HIV-infected patients with lipodystrophy. J Investig Med 53, 1525.

109 JC Lo , K Mulligan , VW Tai , et al. (1998) “Buffalo hump” in men with HIV-1 infection. Lancet 351, 867870.

111 G Guaraldi , G Orlando , N Squillace , et al. (2007) Prevalence of and risk factors for pubic lipoma development in HIV-infected persons. J Acquir Immune Defic Syndr 45, 7276.

114 C Grunfeld , DP Kotler , JK Shigenaga , et al. (1991) Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 90, 154162.

116 J Tomažič , A Silič , P Karner , et al. (2004) Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients. Wien Klin Wochenschr 116, 755759.

117 OA Lesi , KS Soyebi & CN Eboh (2009) Fatty liver and hyperlipidemia in a cohort of HIV-positive Africans on highly active antiretroviral therapy. J Natl Med Assoc 101, 151155.

118 N Friis-Møller , R Weber , P Reiss , et al. (2003) Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 17, 11791193.

120 D Periard , A Telenti , P Sudre , et al. (1999) Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 100, 700705.

121 F van Leth , P Phanuphak , E Stroes , et al. (2004) Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 1, e19.

122 R Jones , S Sawleshwarkar , C Michailidis , et al. (2005) Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 6, 396402.

125 BZ Monnerat , C Cerutti Junior , SC Caniçali , et al. (2008) Clinical and biochemical evaluation of HIV-related lipodystrophy in an ambulatory population from the Hospital Universitário Cassiano Antonio de Morais, Vitória, ES, Brazil. Braz J Infect Dis 12, 364368.

126 H Pernerstorfer-Schoen , B Jilma , A Perschler , et al. (2001) Sex differences in HAART-associated dyslipidaemia. AIDS 15, 725734.

128 AS Foulkes , DA Wohl , I Frank , et al. (2006) Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med 3, e52.

129 M Guardiola , R Ferré , J Salazar , et al. (2006) Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T → C gene variation. Clin Chem 52, 19141919.

132 D Nolan , C Moore , A Castley , et al. (2003) Tumour necrosis factor-α gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17, 121123.

133 E Tarr Philip , P Taffé , G Bleiber , et al. (2005) Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 191, 14191426.

134 NN Abourizk , RW Lyons & GM Madden (1993) Transient state of NIDDM in a patient with AIDS. Diabetes Care 16, 931933.

135 RA Bradbury & K Samaras (2008) Antiretroviral therapy and the human immunodeficiency virus – improved survival but at what cost? Diabetes Obes Metab 10, 441450.

136 JA Eastone & CA Decker (1997) New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 127, 948.

137 F Visnergarwala , KL Krause & DM Musher (1997) Severe diabetes associated with protease inhibitors. Ann Intern Med 127, 947.

138 S van Dieren , JWJ Beulens , YT van der Schouw , et al. (2010) The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 17, Suppl. 1, s3s8.

139 G Danaei , MM Finucane , Y Lu , et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378, 3140.

140 A Carr , J Hudson , J Chuah , et al. (2001) HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 15, 18111822.

141 MP Dubé , RA Parker , P Tebas , et al. (2005) Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 19, 18071818.

143 GA Lee , T Seneviratne , MA Noor , et al. (2004) The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 18, 641649.

144 H Woerle , PR Mariuz , C Meyer , et al. (2003) Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 52, 918925.

145 PC Tien , MF Schneider , SR Cole , et al. (2007) Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 21, 17391745.

147 DA Wohl , G McComsey , P Tebas , et al. (2006) Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 43, 645653.

149 ER de Arruda Junior , HR Lacerda , LCRV Moura , et al. (2010) Risk factors related to hypertension among patients in a cohort living with HIV/AIDS. Braz J Infect Dis 14, 281287.

150 FR Sattler , D Qian , S Louie , et al. (2001) Elevated blood pressure in subjects with lipodystrophy. AIDS 15, 20012010.

152 SS Franklin (2008) Beyond blood pressure: arterial stiffness as a new biomarker of cardiovascular disease. J Am Soc Hypertens 2, 140151.

153 MGA van Vonderen , YM Smulders , CDA Stehouwer , et al. (2009) Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 50, 153161.

155 EC Seaberg , L Benning , AR Sharrett , et al. (2010) Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke 41, 21632170.

156 SS Shankar & MP Dubé (2004) Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. Cardiovasc Toxicol 4, 261269.

157 JH Stein , MA Klein , JL Bellehumeur , et al. (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104, 257262.

159 FJ Torriani , L Komarow , RA Parker , et al. (2008) Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 52, 569576.

160 C Lefèvre , M Auclair , F Boccara , et al. (2010) Premature senescence of vascular cells is induced by HIV protease inhibitors. Arterioscler Thromb Vasc Biol 30, 26112620.

161 B Coll , S Parra , C Alonso-Villaverde , et al. (2006) HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine 34, 5155.

162 L Calza , R Manfredi , D Pocaterra , et al. (2008) Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. J Infect 57, 1632.

163 RC Kaplan , LA Kingsley , SJ Gange , et al. (2008) Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 22, 16151624.

164 K Henry , H Melroe , J Huebsch , et al. (1998) Severe premature coronary artery disease with protease inhibitors. Lancet 351, 1328.

166 SA Bozzette , CF Ake , HK Tam , et al. (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348, 702710.

168 G Barbaro , G Di Lorenzo , A Cirelli , et al. (2003) An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretrovial therapy. Clin Ther 25, 24052418.

169 JE Mallewa , SP Higgins , S Garbett , et al. (2009) Cardiovascular disease risk management in HIV patients, experiences from Greater Manchester. Int J STD AIDS 20, 425426.

170 C Alvarez , R Salazar , J Galindez , et al. (2010) Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis 14, 256263.

171 JJ Schafer , WR Short & KE Squires (2010) Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus. Pharmacotherapy 30, 10721083.

172 A Martin , J Amin , D Cooper , et al. (2010) Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 24, 26572663.

177 N Friis-Møller & SW Worm (2007) Editorial commentary: can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools? Clin Infect Dis 45, 10821084.

178 M May , JA Sterne , M Shipley , et al. (2007) A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol 36, 13091318.

179 E Hammond , E McKinnon & D Nolan (2010) Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 51, 591599.

180 JA Johnson , JB Albu , ES Engelson , et al. (2004) Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 286, E261E271.

184 M Sievers , UA Walker , K Sevastianova , et al. (2009) Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse transcriptase inhibitor-associated lipodystrophy. J Infect Dis 200, 252262.

185 J-P Bastard , M Maachi , JT van Nhieu , et al. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87, 20842089.

187 J Kovsan , R Ben-Romano , SC Souza , et al. (2007) Regulation of adipocyte lipolysis by degradation of the perilipin protein. J Biol Chem 282, 2170421711.

189 A Rudich , R Ben-Romano , S Etzion , et al. (2005) Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand 183, 7588.

190 HH Zhang , M Halbleib , F Ahmad , et al. (2002) Tumor necrosis factor-α stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51, 29292935.

191 M Rydén , E Arvidsson , L Blomqvist , et al. (2004) Targets for TNF-α-induced lipolysis in human adipocytes. Biochem Biophys Res Commun 318, 168175.

192 D Adler-Wailes , EL Guiney , J Koo , et al. (2008) Effects of ritonavir on adipocyte gene expression: evidence for a stress-related response. Obesity 16, 23792387.

195 A Körner , M Wabitsch , B Seidel , et al. (2005) Adiponectin expression in humans is dependent on differentiation of adipocytes and down-regulated by humoral serum components of high molecular weight. Biochem Biophys Res Commun 337, 540550.

196 M Pacenti , L Barzon , F Favaretto , et al. (2006) Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. AIDS 20, 16911705.

198 K Sevastianova , J Sutinen , K Kannisto , et al. (2008) Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 295, E85E91.

204 G Birkus , MJM Hitchcock & T Cihlar (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46, 716723.

206 UA Walker , B Setzer & N Venhoff (2002) Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16, 21652173.

207 E Ribera , JC Paradiñeiro , A Curran , et al. (2008) Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST Study). HIV Clin Trials 9, 407417.

210 M Sension , JL de Andrade Neto , B Grinsztejn , et al. (2009) Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 51, 153162.

214 C Fichtenbaum , JG Gerber , SL Rosenkranz , et al. (2002) Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16, 569577.

215 T Feldt , M Oette , A Kroidl , et al. (2006) Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome. Infection 34, 5561.

216 JM Raboud , C Diong , A Carr , et al. (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11, 3950.

218 JPH van Wijk , AIM Hoepelman , EJP de Koning , et al. (2011) Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. Arterioscler Thromb Vasc Biol 31, 228233.

219 I Jiménez-Nácher , E Alvarez , J Morello , et al. (2011) Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol 7, 457477.

220 E Martínez (2011) Disorders of fat partitioning in treated HIV-infection. Best Prac Res Clin Endocrinol Metab 25, 415427.

222 BM Psaty & CD Furberg (2007) Rosiglitazone and cardiovascular risk. N Engl J Med 356, 25222524.

223 CS Hultman , LE McPhail , JH Donaldson , et al. (2007) Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy. Ann Plas Surg 58, 255263.

224 A Warren & LJ Borud (2008) Excisional lipectomy for HIV-associated cervicodorsal lipodystrophy. Aesthet Surg J 28, 147152.

226 L Skeie , H Bugge , A Negaard , et al. (2010) Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study. HIV Med 11, 170177.

227 C Dollfus , S Blanche , N Trocme , et al. (2009) Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents. HIV Med 10, 263268.

228 P Narciso , R Bucciardini , V Tozzi , et al. (2009) Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study. AIDS Res Hum Retroviruses 25, 979987.

229 G Guaraldi , N Squillace , D De Fazio , et al. (2009) Heterologous fat transplantation for the treatment of HIV-related facial lipoatrophy. Ann Intern Med 150, 6163.

230 L Terry , E Sprinz , R Stein , et al. (2006) Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med Sci Sports Exerc 38, 411417.

231 R Roubenoff , L Weiss , A McDermott , et al. (1999) A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 13, 13731375.

233 KE Yarasheski & R Roubenoff (2001) Exercise treatment for HIV-associated medical and anthropomorphic complications. Exerc Sport Sci Rev 29, 170174.

234 S Fillipas , CL Cherry , F Cicuttini , et al. (2010) The effects of exercise training on metabolic and morphological outcomes for people living with HIV: a systematic review of randomised controlled trials. HIV Clin Trials 11, 270282.

237 B Lindegaard , T Hansen , T Hvid , et al. (2008) The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab 93, 38603869.

238 C Hadigan (2003) Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy. Clin Infect Dis 37, Suppl. 2, S101S104.

239 A Gavrila , S Tsiodras , J Doweiko , et al. (2003) Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study. Clin Infect Dis 36, 15931601.

240 MJ Batterham , R Garsia & PA Greenop (2000) Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy ‘Diet FRS Study’. AIDS 14, 18391843.

241 K Samaras , H Wand , M Law , et al. (2009) Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism. Curr HIV Res 7, 454461.

242 A Barrios , F Blanco , T Garcia-Benayas , et al. (2002) Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 16, 20792081.

244 R Roubenoff , H Schmitz , L Bairos , et al. (2002) Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis 34, 390393.

247 S Benedini , G Perseghin , I Terruzzi , et al. (2009) Effect of l-acetylcarnitine on body composition in HIV-related lipodystrophy. Horm Metab Res 41, 840845.

252 A Balasubramanyam , I Coraza , EO Smith , et al. (2011) Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of “heart positive,” a randomized, controlled trial. J Clin Endocrinol Metab 96, 22362247.

256 E Razzini & GF Baronzio (1993) Omega-3 fatty acids as coadjuvant treatment in AIDS. Med Hypotheses 41, 300305.

258 DA Wohl , HC Tien , M Busby , et al. (2005) Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 41, 14981504.

260 R Manfredi , L Calza & F Chiodo (2004) Polyunsaturated ethyl esters of n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. J Acquir Immune Defic Syndr 36, 878880.

261 J Baril , CM Kovacs , S Trottier , et al. (2007) Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia. HIV Clin Trials 8, 400411.

263 MK Hellerstein , K Wu , M McGrath , et al. (1996) Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immune deficiency syndrome: relation to indices of cytokine production. J Acquir Immune Defic Syndr Hum Retrovirol 11, 258270.

265 N Virgili , M Farriol , JM Castellanos , et al. (1997) Evaluation of immune markers in asymptomatic AIDS patients receiving fish oil supplementation. Clin Nutr 16, 257261.

266 L Normén , B Yip , J Montaner , et al. (2007) Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets. HIV Med 8, 346356.

268 SM Weldon , AC Mullen , CE Loscher , et al. (2007) Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 18, 250258.

270 C Pichard , P Sudre , V Karsegard , et al. (1998) A randomized double-blind controlled study of 6 months of oral nutritional supplementation with arginine and Ω-3 fatty acids in HIV-infected patients. Swiss HIV Cohort Study. AIDS 12, 5363.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Nutrition Research Reviews
  • ISSN: 0954-4224
  • EISSN: 1475-2700
  • URL: /core/journals/nutrition-research-reviews
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 10
Total number of PDF views: 125 *
Loading metrics...

Abstract views

Total abstract views: 281 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 30th May 2017. This data will be updated every 24 hours.